Zai Lab (NASDAQ:ZLAB) Reaches New 12-Month High at $38.64

Zai Lab Ltd (NASDAQ:ZLAB) shares reached a new 52-week high during mid-day trading on Monday . The company traded as high as $38.64 and last traded at $38.64, with a volume of 4141 shares traded. The stock had previously closed at $37.60.

A number of research firms have issued reports on ZLAB. BidaskClub raised shares of Zai Lab from a “hold” rating to a “buy” rating in a research report on Wednesday, November 6th. ValuEngine lowered shares of Zai Lab from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Leerink Swann set a $48.00 price target on shares of Zai Lab and gave the stock a “buy” rating in a research report on Wednesday, September 4th. China Renaissance Securities began coverage on shares of Zai Lab in a research report on Wednesday, September 4th. They set a “buy” rating for the company. Finally, Zacks Investment Research raised shares of Zai Lab from a “sell” rating to a “hold” rating in a research report on Saturday, September 14th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $42.87.

The company has a market capitalization of $2.14 billion, a PE ratio of -14.92 and a beta of 1.33. The business’s 50-day simple moving average is $33.50 and its 200-day simple moving average is $32.34.

Large investors have recently bought and sold shares of the company. Parallel Advisors LLC purchased a new position in shares of Zai Lab during the 2nd quarter valued at approximately $36,000. Advisors Preferred LLC purchased a new position in shares of Zai Lab during the 2nd quarter valued at approximately $54,000. JPMorgan Chase & Co. purchased a new position in shares of Zai Lab during the 2nd quarter valued at approximately $59,000. Aperio Group LLC purchased a new position in shares of Zai Lab during the 2nd quarter valued at approximately $95,000. Finally, Hershey Trust Co. purchased a new position in shares of Zai Lab during the 3rd quarter valued at approximately $148,000. 60.06% of the stock is owned by hedge funds and other institutional investors.

About Zai Lab (NASDAQ:ZLAB)

Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC.

Featured Story: Penny Stocks

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.